Cooperation between Rousselot and xolo boosts progress in 3D bioprinting

Rousselot, known for its expertise in collagen and gelatine, and the German company xolo, which specializes in 3D printing solutions for medical applications, have announced a partnership. The aim of this collaboration is to integrate Rousselot’s X-Pure GelMA into xolo’s bio-inks for volumetric 3D printers. This cooperation is intended to expand the possibilities of bioprinting technology and improve the quality of the biological structures produced.

xolo relies on its patented Xolography technology to print complex cellular structures quickly and accurately. The incorporation of Rousselot’s X-Pure GelMA, a methacrylate-based gelatin, ensures high purity and consistency of bio-inks that are optimal for cell growth. The collaboration focuses on enabling reproducible and stable printing results that meet the requirements of medical research.

“We are dedicated to accelerating medical research by bridging the gap between research and clinical application,” said Tanja Vervust, Director of Rousselot Biomedical, “Our X-Pure range, available in GMP and research-equivalent grades, is ideal for translational research. We are thrilled to collaborate with xolo, a start-up at the forefront of biomedical innovation.”

Stephan Kuehr, Chief Commercial Officer of xolo, added: “Our customers expressed a need for GelMA bio-ink with consistent purity, ready to be used with our volumetric printers, allowing our clients to fully focus on their research without concerns about quality issues. We’re excited to collaborate with Rousselot, which shares our vision for enabling faster, more reliable bioprinting solutions. Together, we can meet these needs by providing high-quality, ready-to-use bioinks that perfectly complement our advanced printing technology, helping researchers push the boundaries of biomedical innovation.”

This collaboration opens up new opportunities for researchers as they now have access to high-quality materials that are crucial for the advancement of bioprinting. In particular, these advances could play an important role in medical research and development.